Endologix, Inc. (ELGX): Price and Financial Metrics
ELGX Price/Volume Stats
| Current price | $0.22 | 52-week high | $7.10 |
| Prev. close | $0.29 | 52-week low | $0.22 |
| Day low | $0.22 | Volume | 7,798,100 |
| Day high | $0.28 | Avg. volume | 1,278,341 |
| 50-day MA | $0.77 | Dividend yield | N/A |
| 200-day MA | $1.58 | Market Cap | 4.22M |
ELGX Stock Price Chart Interactive Chart >
Endologix, Inc. (ELGX) Company Bio
Endologix develops and manufactures minimally invasive treatments for aortic disorders. The company was founded in 1992 and is based in Irvine, California.
Latest ELGX News From Around the Web
Below are the latest news stories about Endologix Inc that investors may wish to consider to help them evaluate ELGX as an investment opportunity.
Endologix plunges 41% after filing for Chapter 11After evaluating a variety of strategic options, Endologix (ELGX) has initiated a voluntary case under Chapter 11 of the U.S. Bankruptcy Code and simultaneously filed a consensual plan of reorganization supported by Deerfield Partners as its largest creditor.The financial reorganization would reduce ~$180M in debt and will provide an ~$30M in additional exit financing.Endologix also... |
Endologix's stock plunges toward record low after bankruptcy filingShares of Endologix Inc. plunged 41% toward a record low in premarket trading Monday, after the medical device maker filed for bankruptcy over the weekend, and announced a deal to be taken private by its largest creditor Deerfield Partners. The company said the reorganization will reduce debt by about $180 million. Endologix also expects $30.8 million in debtor-in-possession financing from Deerfield, an additional $30 million in exit financing from Deerfield and $50 million in rolled over debt. Endologix said it fully intends to meet its financial obligations during the reorganization, including paying its suppliers. The stock had rallied 20.3% over the past three months through Thursday but had tumbled 51.3% year to date, while the S&P 500 has lost 3.1%. |
Endologix Enters into an Agreement with Deerfield Partners to Take the Company PrivateEndologix Enters into an Agreement with Deerfield Partners to Take the Company Private |
Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel HiresSight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced two key hires: Sam Park, joining as Chief Operating Officer, and Jeremy Hayden, who joins as General Counsel and Chief Compliance Officer. |
Edited Transcript of ELGX earnings conference call or presentation 11-May-20 8:30pm GMTQ1 2020 Endologix Inc Earnings Call |
ELGX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -78.43% |
| 5-year | -99.63% |
| YTD | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -78.06% |
| 2018 | -86.54% |
Continue Researching ELGX
Want to do more research on Endologix Inc's stock and its price? Try the links below:Endologix Inc (ELGX) Stock Price | Nasdaq
Endologix Inc (ELGX) Stock Quote, History and News - Yahoo Finance
Endologix Inc (ELGX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...